Management of in-transit melanoma in the time of active systemic therapy | 11 min 1
With up to 14% of patients developing in-transit disease and biologically diverse pathobiological behaviour is observed, in-transit disease is a significant clinical burden. In this presentation, Prof Mark Smithers reviews the current management options for in-transit melanoma.
This was presented at the virtual 2021 Australasian Melanoma Conference, hosted by Melanoma Institute Australia.
It is suitable for Oncologists, Surgeons, Dermatologists, Skin Cancer GPs, General GPs and other healthcare professionals.
Prof Mark Smithers AM
Chairman, Queensland Melanoma Project | Mayne Professor, Discipline of Surgery,
University of Queensland[miniorange_social_login shape="longbuttonwithtext" theme="default" space="4" width="240" height="40"]
Login with your site account
Register a new accountMelanoma Institute Australia uses website cookies to improve your browsing experience when using our website. ACCEPTREJECT